Suárez-Mantilla S, Pineda A, Mendoza-Rojas VC

Language: Spanish
References: 15
Page: 101-104
PDF size: 326.24 Kb.

ABSTRACT

Introduction: multiple complications occur in extremely premature newborns, including metabolic bone disease (MBD). Clinical case: premature neonate of 28.3 weeks, small for gestational age, diagnosed with MBD at 62 days of extrauterine life. MBD was incidentally detected by the presence of multiple fractures of long bones with signs of fraying, images in the calyx of the metaphyseal cup, and changes in bone demineralization. After treatment with vitamin D, both phosphorus and alkaline phosphatase values, as well as radiological values, improved. Conclusions: in all extremely premature newborns, it is necessary to carry out screening for the timely detection of MBD, to avoid possible bone complications.

REFERENCES

1. Osegueda-Mayen JR, Neria-Maguey E, Orozco-Soto LE. Pediátrico criterio. Enfermedad metabólica ósea del prematuro. Acta Pediatr Mex. 2022; 43(4): 253-257. Disponible en: www.actapediatrica.org.mx

2. Schulz EV, Wagner CL. History, epidemiology and prevalence of neonatal bone mineral metabolic disorders. Semin Fetal Neonatal Med. 2020; 25(1): 101069. doi: 10.1016/j.siny.2019.101069.

3. Abrams SA; Committee on Nutrition. Calcium and vitamin d requirements of enterally fed preterm infants. Pediatrics. 2013; 131(5): e1676-1683. doi: 10.1542/peds.2013-0420.

4. Kumar A, Kaur S. Calcium: a nutrient in pregnancy. J Obstet Gynecol India. 2017; 67(5): 313-318. doi: 10.1007/s13224-017-1007-2.

5. Faienza MF, D'Amato E, Natale MP, Grano M, Chiarito M, Brunetti G et al. Metabolic bone disease of prematurity: diagnosis and management. Front Pediatr. 2019; 7: 143. doi: 10.3389/fped.2019.00143.

6. Creed PV, Huff KA, Beard K, DiMeglio LA, Stefanescu BM. Metabolic bone disease of prematurity screening and individualized enteral mineral supplementation in high-risk neonates: a quality improvement initiative. J Perinatol. 2024; 44(9): 1369-1376. doi: 10.1038/s41372-024-01892-9.

7. Pack AM. The association between antiepileptic drugs and bone disease. Epilepsy Curr. 2003; 3(3): 91-95. doi: 10.1046/j.1535-7597.2003.03306.x.

8. Galvis-Blanco SJ, Duarte-Bueno LM, Villarreal-Gómez A, Niño-Tovar MA, Africano-León ML, Ortega-Sierra OL. Enfermedad ósea metabólica del prematuro: revisión de tema. Rev Méd UIS. 2022; 35(2): 131-142. doi: 10.18273/revmed.v35n2-2022012.

9. Brado L, Brado L, Matheisl D, Klotz D, Mildenberger E, Kidszun A. A European perspective on metabolic bone disease of prematurity. Z Geburtshilfe Neonatol. 2023; 227(03): e30-e31. doi: 10.1055/s-0043-1769231.

10. Argente OJ, Soriano GL. Capítulo 171: Alteraciones del metabolismo fosfocálcico. En: Manual de endocrinología Pediátrica. 2a ed. Madrid: Ergon; 2014.

11. Forster C, Hoodbhoy S, Macdougall C, King K, Gooding N, Mak K et al. Practical approach to managing metabolic bone disease of prematurity in the neonatal unit. Arch Dis Child Educ Pract Ed. 2024; 109(3): 143-146. doi: 10.1136/archdischild-2023-326100.

12. Ruiz E, Piamonte DE, Gómez DT, Díaz LA, Pérez LA. Incidence of metabolic bone disease in neonates under 32 gestational weeks at the Hospital Universitario de Santander in Colombia. Biomedica. 2024; 44(1): 35-44.

13. Lü KL, Xie SS, Hu Q, Yang ZY, Fan Q li, Liu E et al. Diagnostic markers of metabolic bone disease of prematurity in preterm infants. Bone. 2023; 169: 116656. doi: 10.1016/j.bone.2022.116656.

14. Jiang H, Guo J, Li J, Li C, Du W, Canavese F et al. Artificial neural network modeling to predict neonatal metabolic bone disease in the prenatal and postnatal periods. JAMA Netw Open. 2023; 6(1): e2251849. doi: 10.1001/jamanetworkopen.2022.51849.

15. Motte-Signoret E, Jlassi M, Lecoq L, Wachter PY, Durandy A, Boileau P. Early elevated alkaline phosphatase as a surrogate biomarker of ongoing metabolic bone disease of prematurity. Eur J Pediatr. 2023; 182(4): 1829-1837. doi: 10.1007/s00431-023-04839-y.